(Q24193083)

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Long-term effects of ranibizumab on diabetic retinopathy severity and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

The pathogenesis of edema in diabetic maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreal bevacizumab for diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Risk factors for diffuse and focal macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Current approaches to the management of diabetic retinopathy and diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Diabetic maculopathy. A critical review highlighting diffuse macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Corticosteroids in posterior segment disease: an update on new delivery systems and new indications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Meta-analysis and review on the effect of bevacizumab in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreal steroids for macular edema in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

GRADE guidelines 6. Rating the quality of evidence—imprecision

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Revolution to a new standard treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreous dexamethasone effects on different patterns of diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

The importance of fluorescein angiography in planning laser treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Long-term effectiveness of modified grid laser photocoagulation for diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

A review of clinical trials of anti-VEGF agents for diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Interventions for diabetic macular oedema: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Improving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: a prospective, multicentre, UK study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Anti-vascular endothelial growth factor agents for diabetic maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Economic considerations of macular edema therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Allowing for uncertainty due to missing data in meta-analysis--part 1: two-stage methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Epidemiology of diabetic retinopathy and macular oedema: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Systemic safety of ranibizumab for diabetic macular edema: meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Treatment of macular edema in diabetic retinopathy: comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

Abnormalities of the foveal avascular zone in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

Photocoagulation for Diabetic Macular Edema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

The role of capillary perfusion in the management of diabetic macular edema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

The evidence provided by a single trial is less reliable than its statistical analysis suggests

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

Angiogenic pathways in diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

1 reference

7 January 2021

Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

Diabetic macular edema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007419.PUB4

7 January 2021

10.1002/14651858.CD007419.PUB4

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

25342124

1 reference

Consolidated OpenCitations Corpus – April 2017